Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M333Revenue $M34.7Net Margin (%)-55.3Z-Score-35.8
Enterprise Value $M314EPS $-0.4Operating Margin %-48.6F-Score6
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-56.3Higher ROA y-yY
Price/Book17.110-y EBITDA Growth Rate %-46.5Quick Ratio1.8Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %-45.4Current Ratio1.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-61.5Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-204.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M150ROI % (ttm)-75.7Gross Margin Increase y-yY

Gurus Latest Trades with CTIC

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

CTIC is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CTIC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BIANCO LOUIS AEVP, Finance & Administration 2014-11-06Sell10,000$2.37-8.44 view
Plunkett MatthewEVP, Corporate Development 2014-11-04Sell12,000$2.39-9.21 view
Plunkett MatthewEVP, Corporate Development 2014-10-06Sell12,000$2.39-9.21 view
Plunkett MatthewEVP, Corporate Development 2014-09-23Sell103,635$2.56-15.23 view
BIANCO JAMES APresident and CEO 2014-09-22Sell307,068$2.53-14.23 view
BIANCO LOUIS AEVP, Finance & Administration 2014-09-19Sell145,000$2.59-16.22 view
Plunkett MatthewEVP, Corporate Development 2014-09-04Sell27,301$2.48-12.5 view
BIANCO JAMES APresident and CEO 2014-08-15Sell40,000$2.54-14.57 view
Plunkett MatthewEVP, Corporate Development 2014-08-04Sell12,000$2.48-12.5 view
BIANCO LOUIS AEVP, Finance & Administration 2014-07-10Sell10,000$2.73-20.51 view

Press Releases about CTIC :

    Quarterly/Annual Reports about CTIC:

    News about CTIC:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
    These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
    comment on CTIC Dec 16 2011 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
    Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

    More From Other Websites
    CTI BioPharma to Present at the Upcoming Investor Conferences Nov 17 2014
    CTI BioPharma to Present at the Upcoming Investor Conferences Nov 17 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Nov 13 2014
    CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock Nov 07 2014
    CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock Nov 07 2014
    CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock Nov 06 2014
    CTI BIOPHARMA CORP Files SEC form 8-K/A, Financial Statements and Exhibits Nov 06 2014
    CTI BIOPHARMA CORP Financials Nov 06 2014
    10-Q for CTI BioPharma Corp. Nov 03 2014
    Avviso di deposito della Relazione Trimestrale su modulo 10-Q relativa al trimestre chiuso il 30... Oct 31 2014
    CTI BIOPHARMA CORP Files SEC form 10-Q, Quarterly Report Oct 31 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Oct 30 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Oct 29 2014
    CTi Biopharma Corp Earnings Call scheduled for 4:30 pm ET today Oct 29 2014
    CTI BioPharma Reports Third Quarter 2014 Financial Results Oct 29 2014
    Q3 2014 CTi Biopharma Corp Earnings Release - After Market Close Oct 29 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Oct 27 2014
    CTI BioPharma Corp. becomes Vernalis’ worldwide licensee for tosedostat Oct 27 2014
    CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer Therapy Oct 27 2014
    CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer Therapy Oct 27 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK